Modified release ibuprofen dosage form
AssigneeSCOLR Pharma, Inc.
InventorsMichael Hite, Cathy Federici, Alan Brunelle, Stephen Turner
Life of this patent
Estimating the term…
Abstract
The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 μg/ml over an extended period of at least 8 hours following administering of a single dose.
Claims22
A solid dosage form for modified oral administration of ibuprofen comprising:
- two or more hydrophilic polymers having two different viscosities, wherein the two different viscosities are at least one order of magnitude apart from one another;
- 300 to 800 mg of ibuprofen in the solid dosage form uniformly dispersed in said polymer;
- a dissolution additive dispersed in said two or more hydrophilic polymers in an amount in the range of 10% to 35% by weight of the ibuprofen, said dissolution additive comprising an alkali metal salt, an amino acid having a neutral to alkaline side chain, croscarmellose or a salt thereof, or a combination of any two of such dissolution additives;
- and
- an inert formulation additive dispersed in said two or more hydrophilic polymers in an amount in the range of 15% to 75% by weight of the ibuprofen, said formulation additive comprising microcrystalline cellulose, silica, magnesium stearate, stearic acid, lactose, pre-gelatinized starch, dicalcium phosphate or a combination of any of them,
- wherein said solid dosage form comprises a monolithic, directly compressed tablet and releases at least 20% of the ibuprofen within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter releases ibuprofen at a relatively constant rate over a period of at least 8 hours, and wherein at least 70% of the ibuprofen is released over a period of not more than 14 hours following such administration or exposure.
A solid dosage form for modified oral administration of ibuprofen comprising:
- a first hydrophilic polymer comprising hydroxypropyl methylcellulose having a viscosity of about 100 cps and a second hydrophilic polymer comprising hydroxypropyl methylcellulose having a viscosity of between about 4000 cps to about 100,000 cps;
- 300 to 800 mg of ibuprofen in the solid dosage form uniformly dispersed in said first hydrophilic polymer and said second hydrophilic polymer;
- a dissolution additive dispersed in said first hydrophilic polymer and in said second hydrophilic polymer in an amount in the range of 10% to 35% by weight of the ibuprofen, said dissolution additive comprising glycine and croscarmellose sodium;
- and
- a first inert formulation additive comprising a first microcrystalline cellulose having a first average particle size and a second inert formulation additive comprising a second microcrystalline cellulose having a second average particle size, wherein each such microcrystalline cellulose is present at a concentration in the range of about 15% to about 35% by weight of the ibuprofen, the combination of which comprises from about 40% to about 60% by weight of the ibuprofen, wherein said first formulation additive and said second inert formulation additive are dispersed in said first hydrophilic polymer and said second hydrophilic polymer;
- wherein said solid dosage form comprises a monolithic, directly compressed tablet and releases at least 20% of the ibuprofen within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter releases ibuprofen at a relatively constant rate over a period of at least 8 hours, and wherein at least 70% of the ibuprofen is released over a period of not more than 14 hours following such administration or exposure.
A method for providing immediate and extended release of ibuprofen to a subject, comprising administering to a subject in a single dosage form comprising a monolithic, directly compressed tablet, said tablet comprising:
- two or more hydrophilic polymers having two different viscosities, wherein the two different viscosities are at least one order of magnitude apart from one another;
- 300 to 800 mg of ibuprofen in the solid dosage form uniformly dispersed in said two or more hydrophilic polymers;
- a dissolution additive dispersed in said two or more hydrophilic polymers in an amount in the range of 10% to 35% by weight of the ibuprofen, said dissolution additive comprising an alkali metal salt, an amino acid having a neutral to alkaline side chain, croscarmellose or a salt thereof, or a combination of any two of such dissolution additives;
- and
- an inert formulation additive dispersed in said two or more hydrophilic polymers in an amount in the range of 15% to 75% by weight of the ibuprofen, said formulation additive comprising microcrystalline cellulose, silica, magnesium stearate, stearic acid, lactose, pre-gelatinized starch, dicalcium phosphate or a combination of any of them,
- wherein said tablet releases at least 20% of the ibuprofen within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter releases ibuprofen at a relatively constant rate over a period of at least 8 hours, and wherein at least 70% of the ibuprofen is released over a period of not more than 14 hours following such administration or exposure.
Dependencies are inferred from the claim text.